| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 65 | 2023 | 364 | 11.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2021 | 70 | 2.650 |
Why?
|
| Child | 114 | 2022 | 6405 | 2.570 |
Why?
|
| Lebanon | 40 | 2023 | 67 | 2.440 |
Why?
|
| Antisickling Agents | 9 | 2020 | 20 | 2.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2020 | 245 | 2.070 |
Why?
|
| Bone Neoplasms | 11 | 2022 | 100 | 1.980 |
Why?
|
| Hydroxyurea | 8 | 2020 | 57 | 1.950 |
Why?
|
| Child, Preschool | 70 | 2022 | 3187 | 1.820 |
Why?
|
| Blood Transfusion | 13 | 2020 | 205 | 1.720 |
Why?
|
| Brain Infarction | 4 | 2020 | 54 | 1.710 |
Why?
|
| Adolescent | 90 | 2021 | 8912 | 1.690 |
Why?
|
| Osteosarcoma | 7 | 2020 | 35 | 1.520 |
Why?
|
| beta-Thalassemia | 5 | 2021 | 17 | 1.450 |
Why?
|
| Phlebotomy | 3 | 2020 | 17 | 1.370 |
Why?
|
| Erythrocyte Transfusion | 5 | 2020 | 72 | 1.360 |
Why?
|
| Humans | 184 | 2023 | 68618 | 1.280 |
Why?
|
| Hemoglobin, Sickle | 9 | 2022 | 22 | 1.280 |
Why?
|
| Methotrexate | 7 | 2020 | 91 | 1.180 |
Why?
|
| Transplantation Conditioning | 5 | 2020 | 34 | 1.160 |
Why?
|
| Male | 118 | 2022 | 37321 | 1.130 |
Why?
|
| Infant | 41 | 2022 | 2891 | 1.080 |
Why?
|
| Female | 113 | 2022 | 38074 | 1.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 468 | 1.020 |
Why?
|
| Pain | 8 | 2022 | 472 | 1.020 |
Why?
|
| Developing Countries | 4 | 2019 | 106 | 1.010 |
Why?
|
| Sarcoma, Ewing | 6 | 2020 | 26 | 0.980 |
Why?
|
| Retrospective Studies | 40 | 2022 | 7277 | 0.870 |
Why?
|
| Neutropenia | 8 | 2019 | 72 | 0.870 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2019 | 18 | 0.830 |
Why?
|
| Neoplasms | 12 | 2020 | 1667 | 0.820 |
Why?
|
| Palliative Care | 3 | 2013 | 271 | 0.790 |
Why?
|
| Acute Chest Syndrome | 3 | 2022 | 19 | 0.740 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 55 | 0.730 |
Why?
|
| Osteomyelitis | 1 | 2020 | 40 | 0.720 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2020 | 62 | 0.700 |
Why?
|
| Centromere | 1 | 2019 | 15 | 0.690 |
Why?
|
| Aneuploidy | 1 | 2019 | 21 | 0.680 |
Why?
|
| Hypertension, Pulmonary | 3 | 2011 | 232 | 0.680 |
Why?
|
| Quality of Health Care | 2 | 2013 | 322 | 0.670 |
Why?
|
| Etoposide | 1 | 2019 | 64 | 0.660 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 144 | 0.660 |
Why?
|
| Hematologic Neoplasms | 3 | 2017 | 37 | 0.660 |
Why?
|
| Mutation | 8 | 2022 | 1213 | 0.650 |
Why?
|
| Anemia, Aplastic | 2 | 2017 | 10 | 0.630 |
Why?
|
| Fetal Blood | 11 | 2011 | 131 | 0.620 |
Why?
|
| Cisplatin | 1 | 2019 | 192 | 0.620 |
Why?
|
| Prognosis | 14 | 2020 | 2093 | 0.610 |
Why?
|
| Vidarabine | 1 | 2017 | 12 | 0.600 |
Why?
|
| Doxorubicin | 1 | 2019 | 231 | 0.600 |
Why?
|
| Iron Overload | 3 | 2017 | 28 | 0.600 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2014 | 268 | 0.600 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2022 | 373 | 0.590 |
Why?
|
| Stroke | 12 | 2020 | 2163 | 0.590 |
Why?
|
| Asparaginase | 4 | 2017 | 7 | 0.580 |
Why?
|
| Adult | 48 | 2022 | 21403 | 0.580 |
Why?
|
| Follow-Up Studies | 17 | 2022 | 3259 | 0.570 |
Why?
|
| Hospitalization | 3 | 2020 | 978 | 0.570 |
Why?
|
| Hemoglobins | 5 | 2021 | 120 | 0.540 |
Why?
|
| Antineoplastic Agents | 5 | 2012 | 1070 | 0.520 |
Why?
|
| Young Adult | 22 | 2021 | 5717 | 0.500 |
Why?
|
| Treatment Outcome | 22 | 2022 | 7029 | 0.500 |
Why?
|
| alpha-Globins | 1 | 2014 | 1 | 0.490 |
Why?
|
| alpha-Thalassemia | 1 | 2014 | 7 | 0.490 |
Why?
|
| Venous Thrombosis | 2 | 2021 | 125 | 0.490 |
Why?
|
| Ferritins | 3 | 2010 | 49 | 0.480 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 319 | 0.480 |
Why?
|
| Caregivers | 2 | 2015 | 365 | 0.470 |
Why?
|
| Cerebrovascular Circulation | 7 | 2013 | 296 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 446 | 0.460 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2011 | 30 | 0.460 |
Why?
|
| Limb Salvage | 3 | 2022 | 39 | 0.460 |
Why?
|
| Bone Marrow Transplantation | 7 | 2000 | 149 | 0.460 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 189 | 0.460 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 50 | 0.440 |
Why?
|
| Cerebrovascular Disorders | 6 | 2017 | 182 | 0.440 |
Why?
|
| Graft vs Host Disease | 6 | 2020 | 163 | 0.440 |
Why?
|
| Thrombophilia | 2 | 2011 | 21 | 0.440 |
Why?
|
| Benzaldehydes | 3 | 2022 | 8 | 0.430 |
Why?
|
| Pyrimidines | 2 | 2012 | 178 | 0.430 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 371 | 0.430 |
Why?
|
| Piperazines | 2 | 2012 | 206 | 0.420 |
Why?
|
| Pyrazines | 3 | 2022 | 46 | 0.420 |
Why?
|
| Sinus Thrombosis, Intracranial | 3 | 2021 | 20 | 0.420 |
Why?
|
| Cerebral Infarction | 5 | 2011 | 103 | 0.410 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 63 | 0.410 |
Why?
|
| Siderophores | 2 | 2010 | 16 | 0.400 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 10 | 2013 | 99 | 0.390 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 11 | 0.390 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 447 | 0.390 |
Why?
|
| Deferoxamine | 2 | 2010 | 45 | 0.390 |
Why?
|
| Pyrazoles | 3 | 2022 | 190 | 0.390 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 425 | 0.390 |
Why?
|
| Pancreatitis | 2 | 2010 | 279 | 0.390 |
Why?
|
| Secondary Prevention | 3 | 2020 | 291 | 0.380 |
Why?
|
| Retinoblastoma | 2 | 2022 | 26 | 0.380 |
Why?
|
| Retinal Neoplasms | 2 | 2022 | 22 | 0.380 |
Why?
|
| Chelation Therapy | 1 | 2010 | 17 | 0.370 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 12 | 0.370 |
Why?
|
| Factor V | 2 | 2011 | 20 | 0.370 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 32 | 0.370 |
Why?
|
| Bereavement | 1 | 2011 | 39 | 0.370 |
Why?
|
| Transplantation, Homologous | 5 | 2017 | 242 | 0.360 |
Why?
|
| Wernicke Encephalopathy | 1 | 2010 | 5 | 0.360 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 22 | 0.360 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 6 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2018 | 2223 | 0.350 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 8 | 2000 | 74 | 0.350 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 1 | 0.350 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 52 | 0.350 |
Why?
|
| Quality of Life | 4 | 2021 | 1515 | 0.350 |
Why?
|
| Renal Veins | 1 | 2009 | 18 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 331 | 0.340 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 9 | 0.340 |
Why?
|
| Parents | 2 | 2011 | 312 | 0.320 |
Why?
|
| Genotype | 5 | 2021 | 786 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 511 | 0.320 |
Why?
|
| Pulmonary Blastoma | 2 | 2006 | 7 | 0.320 |
Why?
|
| Lead | 1 | 2008 | 45 | 0.310 |
Why?
|
| Infant, Newborn | 14 | 2021 | 2455 | 0.310 |
Why?
|
| Factor XIII Deficiency | 1 | 2008 | 3 | 0.310 |
Why?
|
| Splenic Rupture | 1 | 2008 | 5 | 0.310 |
Why?
|
| Gene Frequency | 2 | 2021 | 207 | 0.310 |
Why?
|
| Factor XIII | 1 | 2008 | 31 | 0.300 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2020 | 2 | 0.300 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 2 | 2020 | 4 | 0.300 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 36 | 0.300 |
Why?
|
| Primary Prevention | 2 | 2020 | 115 | 0.300 |
Why?
|
| Cause of Death | 2 | 2020 | 241 | 0.300 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 34 | 0.300 |
Why?
|
| Incidence | 7 | 2021 | 1603 | 0.300 |
Why?
|
| Femoral Neoplasms | 2 | 2022 | 7 | 0.300 |
Why?
|
| Sickle Cell Trait | 2 | 2013 | 24 | 0.300 |
Why?
|
| Asthma | 1 | 2011 | 345 | 0.300 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 349 | 0.290 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2022 | 4 | 0.290 |
Why?
|
| Cognition | 3 | 2020 | 513 | 0.280 |
Why?
|
| Chest Pain | 3 | 2006 | 151 | 0.280 |
Why?
|
| Liver | 3 | 2010 | 1118 | 0.280 |
Why?
|
| Sarcoma | 2 | 2022 | 70 | 0.280 |
Why?
|
| Kidney Neoplasms | 3 | 2017 | 206 | 0.280 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 1996 | 101 | 0.280 |
Why?
|
| Cyclophosphamide | 5 | 2017 | 129 | 0.280 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 233 | 0.280 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 46 | 0.270 |
Why?
|
| Brain | 7 | 2011 | 2176 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 931 | 0.270 |
Why?
|
| Vincristine | 3 | 2022 | 44 | 0.270 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2006 | 33 | 0.270 |
Why?
|
| Iron | 1 | 2008 | 197 | 0.260 |
Why?
|
| Lung Neoplasms | 4 | 2010 | 1173 | 0.260 |
Why?
|
| Heparin | 2 | 2021 | 205 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 786 | 0.260 |
Why?
|
| Polymorphism, Genetic | 3 | 2016 | 301 | 0.260 |
Why?
|
| Poloxamer | 2 | 2021 | 10 | 0.250 |
Why?
|
| Cross-Sectional Studies | 7 | 2021 | 2279 | 0.250 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 18 | 0.240 |
Why?
|
| Antigens, CD34 | 11 | 1995 | 75 | 0.240 |
Why?
|
| Hemolysis | 3 | 2022 | 39 | 0.240 |
Why?
|
| Butyrates | 2 | 2014 | 14 | 0.230 |
Why?
|
| Acute Pain | 2 | 2021 | 35 | 0.230 |
Why?
|
| Thrombocytopenia | 5 | 2014 | 122 | 0.230 |
Why?
|
| Bone Marrow | 10 | 2020 | 168 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2017 | 291 | 0.220 |
Why?
|
| Blood Flow Velocity | 7 | 2013 | 172 | 0.220 |
Why?
|
| Altruism | 1 | 2023 | 24 | 0.220 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 14 | 0.210 |
Why?
|
| Cognition Disorders | 1 | 2006 | 342 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 104 | 0.210 |
Why?
|
| Health Resources | 1 | 2023 | 76 | 0.210 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2022 | 6 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 4 | 0.210 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2022 | 9 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 332 | 0.210 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 16 | 0.200 |
Why?
|
| Homozygote | 3 | 2016 | 119 | 0.200 |
Why?
|
| Status Epilepticus | 1 | 2022 | 74 | 0.190 |
Why?
|
| beta-Globins | 1 | 2021 | 4 | 0.190 |
Why?
|
| Codon | 1 | 2021 | 21 | 0.190 |
Why?
|
| Disease Management | 5 | 2021 | 248 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 306 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 3 | 2017 | 561 | 0.190 |
Why?
|
| Age Factors | 5 | 2013 | 1864 | 0.190 |
Why?
|
| Osteopetrosis | 1 | 2020 | 8 | 0.190 |
Why?
|
| Transfusion Reaction | 3 | 2010 | 33 | 0.190 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2020 | 1 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 649 | 0.180 |
Why?
|
| Bone Resorption | 1 | 2020 | 64 | 0.180 |
Why?
|
| Neuroblastoma | 3 | 2017 | 109 | 0.180 |
Why?
|
| Risk Factors | 11 | 2021 | 5731 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2000 | 117 | 0.180 |
Why?
|
| Vascular Diseases | 3 | 2010 | 94 | 0.180 |
Why?
|
| Middle Aged | 12 | 2021 | 21147 | 0.180 |
Why?
|
| Vascular Access Devices | 1 | 2020 | 21 | 0.180 |
Why?
|
| Vasodilator Agents | 1 | 2021 | 138 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 29 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 1997 | 24 | 0.180 |
Why?
|
| Absorptiometry, Photon | 2 | 2011 | 83 | 0.180 |
Why?
|
| Fever | 3 | 2021 | 96 | 0.180 |
Why?
|
| Bone Remodeling | 2 | 2011 | 45 | 0.180 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 7 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2000 | 74 | 0.180 |
Why?
|
| Biopsy, Needle | 3 | 2010 | 191 | 0.180 |
Why?
|
| Survival Rate | 5 | 2020 | 1056 | 0.180 |
Why?
|
| Hospitals, University | 2 | 2019 | 169 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 69 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2020 | 79 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 91 | 0.170 |
Why?
|
| Mercaptopurine | 2 | 2016 | 9 | 0.170 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2019 | 4 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 89 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 2 | 1997 | 62 | 0.170 |
Why?
|
| Tertiary Care Centers | 4 | 2022 | 67 | 0.170 |
Why?
|
| Bone Density | 2 | 2011 | 159 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 18 | 0.170 |
Why?
|
| DNA Modification Methylases | 1 | 2019 | 24 | 0.170 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 27 | 0.170 |
Why?
|
| Internationality | 1 | 2019 | 74 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2021 | 206 | 0.170 |
Why?
|
| Wilms Tumor | 2 | 2016 | 47 | 0.170 |
Why?
|
| Anemia, Hemolytic | 4 | 2009 | 37 | 0.160 |
Why?
|
| Neutrophils | 5 | 2017 | 204 | 0.160 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2011 | 181 | 0.160 |
Why?
|
| Health Surveys | 1 | 2021 | 489 | 0.160 |
Why?
|
| Anemia, Sideroblastic | 1 | 2018 | 1 | 0.160 |
Why?
|
| MELAS Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
|
| Double-Blind Method | 6 | 2021 | 1738 | 0.160 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 2018 | 2 | 0.160 |
Why?
|
| Hematopoiesis | 8 | 1994 | 108 | 0.160 |
Why?
|
| Acidosis, Lactic | 1 | 2018 | 6 | 0.160 |
Why?
|
| Base Sequence | 3 | 2017 | 1015 | 0.160 |
Why?
|
| Cell Differentiation | 5 | 2017 | 1034 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 22 | 0.160 |
Why?
|
| Ribs | 1 | 2018 | 25 | 0.160 |
Why?
|
| Interleukin-3 | 8 | 1996 | 63 | 0.160 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 43 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 37 | 0.160 |
Why?
|
| Talus | 1 | 2018 | 18 | 0.160 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 24 | 0.160 |
Why?
|
| Refugees | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cell Separation | 5 | 1995 | 132 | 0.160 |
Why?
|
| Thiamine | 2 | 2010 | 11 | 0.150 |
Why?
|
| Fetal Hemoglobin | 3 | 2014 | 10 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 492 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2021 | 403 | 0.150 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 113 | 0.150 |
Why?
|
| Carcinoma, Medullary | 1 | 2017 | 7 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 239 | 0.150 |
Why?
|
| Histocompatibility Testing | 1 | 2017 | 38 | 0.150 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 13 | 0.150 |
Why?
|
| Child Health Services | 1 | 2018 | 50 | 0.150 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2017 | 19 | 0.150 |
Why?
|
| Monosomy | 1 | 1997 | 6 | 0.150 |
Why?
|
| Hemolytic Plaque Technique | 1 | 2017 | 4 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 1465 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 32 | 0.140 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 4 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 561 | 0.140 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2017 | 15 | 0.140 |
Why?
|
| Pregnancy | 5 | 2017 | 2334 | 0.140 |
Why?
|
| Research Design | 3 | 2019 | 729 | 0.140 |
Why?
|
| Autoimmune Diseases | 3 | 2003 | 186 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 1997 | 74 | 0.140 |
Why?
|
| Pyrophosphatases | 1 | 2016 | 6 | 0.140 |
Why?
|
| Methyltransferases | 1 | 2016 | 19 | 0.140 |
Why?
|
| Leukemia | 4 | 2011 | 117 | 0.140 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 58 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2017 | 122 | 0.140 |
Why?
|
| Phospholipases A | 2 | 2006 | 41 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 94 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2019 | 219 | 0.140 |
Why?
|
| Child Nutrition Disorders | 1 | 2016 | 5 | 0.140 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 508 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1851 | 0.140 |
Why?
|
| Cytokines | 1 | 2000 | 866 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1745 | 0.140 |
Why?
|
| Lung Diseases | 3 | 2006 | 175 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 597 | 0.130 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2015 | 3 | 0.130 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2015 | 9 | 0.130 |
Why?
|
| Dexamethasone | 2 | 2020 | 150 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1997 | 116 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2017 | 195 | 0.130 |
Why?
|
| Malnutrition | 1 | 2016 | 28 | 0.130 |
Why?
|
| Remission Induction | 3 | 2012 | 111 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 115 | 0.130 |
Why?
|
| Ceftriaxone | 1 | 2015 | 32 | 0.130 |
Why?
|
| Vaccines, Conjugate | 1 | 2015 | 11 | 0.130 |
Why?
|
| Pedigree | 3 | 2017 | 159 | 0.130 |
Why?
|
| Risk | 5 | 2011 | 563 | 0.130 |
Why?
|
| Family | 2 | 2014 | 293 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 30 | 0.120 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 55 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1996 | 142 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 2015 | 90 | 0.120 |
Why?
|
| Imatinib Mesylate | 2 | 2012 | 26 | 0.120 |
Why?
|
| Peer Group | 1 | 2015 | 104 | 0.120 |
Why?
|
| Mutagens | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Mutation, Missense | 2 | 2018 | 112 | 0.120 |
Why?
|
| Priapism | 1 | 2014 | 4 | 0.120 |
Why?
|
| Acute Disease | 7 | 2011 | 658 | 0.120 |
Why?
|
| Environmental Illness | 1 | 2013 | 1 | 0.120 |
Why?
|
| Antigens, CD | 8 | 1995 | 230 | 0.110 |
Why?
|
| Schools | 1 | 2015 | 156 | 0.110 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hair Diseases | 1 | 2013 | 11 | 0.110 |
Why?
|
| Alanine Transaminase | 2 | 2010 | 137 | 0.110 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 44 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2015 | 369 | 0.110 |
Why?
|
| Disease Progression | 3 | 2014 | 1038 | 0.110 |
Why?
|
| Air Pollution | 1 | 2013 | 54 | 0.110 |
Why?
|
| Bacteremia | 1 | 2015 | 155 | 0.110 |
Why?
|
| Hospitals, Pediatric | 2 | 2011 | 114 | 0.110 |
Why?
|
| Teicoplanin | 1 | 2012 | 5 | 0.110 |
Why?
|
| Benzamides | 2 | 2012 | 156 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 581 | 0.110 |
Why?
|
| Atrioventricular Block | 1 | 2012 | 5 | 0.110 |
Why?
|
| Hematinics | 1 | 2013 | 52 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2013 | 82 | 0.110 |
Why?
|
| Analgesics | 2 | 2018 | 118 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2017 | 753 | 0.110 |
Why?
|
| Educational Status | 2 | 2021 | 273 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2019 | 2007 | 0.110 |
Why?
|
| Syndrome | 5 | 2006 | 255 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 772 | 0.100 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2012 | 10 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2012 | 33 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2017 | 1330 | 0.100 |
Why?
|
| Recombinant Proteins | 9 | 1995 | 742 | 0.100 |
Why?
|
| Social Support | 1 | 2015 | 423 | 0.100 |
Why?
|
| Time Factors | 5 | 2018 | 4655 | 0.100 |
Why?
|
| Bone Marrow Cells | 6 | 1994 | 217 | 0.100 |
Why?
|
| Pain Management | 1 | 2013 | 186 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2020 | 3705 | 0.100 |
Why?
|
| Biomarkers | 5 | 2022 | 1593 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 156 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 83 | 0.090 |
Why?
|
| Anthropometry | 1 | 2011 | 64 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2013 | 682 | 0.090 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 13 | 0.090 |
Why?
|
| Agranulocytosis | 2 | 1989 | 15 | 0.090 |
Why?
|
| Professional-Family Relations | 1 | 2011 | 45 | 0.090 |
Why?
|
| Xanthine Oxidase | 1 | 2010 | 15 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 87 | 0.090 |
Why?
|
| Allopurinol | 1 | 2010 | 36 | 0.090 |
Why?
|
| Acculturation | 1 | 2010 | 25 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 378 | 0.090 |
Why?
|
| Hip Joint | 1 | 2011 | 64 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 7 | 1995 | 78 | 0.090 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2010 | 5 | 0.090 |
Why?
|
| Complementary Therapies | 1 | 2010 | 43 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2015 | 824 | 0.090 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 117 | 0.090 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Acrodermatitis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 714 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2324 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2000 | 71 | 0.090 |
Why?
|
| Biotin | 1 | 2010 | 28 | 0.090 |
Why?
|
| Myokymia | 1 | 2010 | 2 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 112 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 334 | 0.090 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 34 | 0.090 |
Why?
|
| Alemtuzumab | 1 | 2009 | 10 | 0.090 |
Why?
|
| Interleukin-1 | 4 | 1999 | 86 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 117 | 0.090 |
Why?
|
| Otitis Media with Effusion | 2 | 2000 | 9 | 0.090 |
Why?
|
| Tibia | 1 | 2010 | 93 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1140 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 40 | 0.090 |
Why?
|
| Hematuria | 1 | 2009 | 24 | 0.090 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2009 | 13 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 35 | 0.080 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 16 | 0.080 |
Why?
|
| Headache | 2 | 2021 | 68 | 0.080 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 159 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2011 | 222 | 0.080 |
Why?
|
| Point Mutation | 1 | 2009 | 97 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2015 | 411 | 0.080 |
Why?
|
| Myofibromatosis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Vinblastine | 1 | 2009 | 40 | 0.080 |
Why?
|
| Hematopoietic Cell Growth Factors | 5 | 1994 | 22 | 0.080 |
Why?
|
| Abdomen | 1 | 2009 | 80 | 0.080 |
Why?
|
| Sirolimus | 1 | 2009 | 118 | 0.080 |
Why?
|
| Bone Lengthening | 1 | 2008 | 11 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 338 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2015 | 2358 | 0.080 |
Why?
|
| Extremities | 1 | 2008 | 49 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 151 | 0.080 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2008 | 4 | 0.080 |
Why?
|
| Dura Mater | 1 | 2008 | 23 | 0.080 |
Why?
|
| Osteonecrosis | 1 | 2008 | 20 | 0.080 |
Why?
|
| Hip | 1 | 2008 | 19 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 800 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2009 | 68 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 767 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2022 | 159 | 0.080 |
Why?
|
| Animals | 11 | 2020 | 20881 | 0.080 |
Why?
|
| Intelligence Tests | 2 | 2006 | 32 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 45 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2008 | 17 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 103 | 0.080 |
Why?
|
| Milk | 1 | 2008 | 43 | 0.080 |
Why?
|
| Hemosiderosis | 1 | 2008 | 7 | 0.080 |
Why?
|
| Hemorrhagic Disorders | 1 | 2008 | 7 | 0.080 |
Why?
|
| Anesthetics, Intravenous | 1 | 2008 | 27 | 0.080 |
Why?
|
| Rupture, Spontaneous | 1 | 2008 | 21 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2800 | 0.080 |
Why?
|
| Bacterial Infections | 2 | 2000 | 163 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 14862 | 0.080 |
Why?
|
| Propofol | 1 | 2008 | 36 | 0.080 |
Why?
|
| Placebos | 2 | 2021 | 195 | 0.080 |
Why?
|
| Anemia, Macrocytic | 2 | 1996 | 4 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 201 | 0.070 |
Why?
|
| Transferrin | 1 | 2008 | 94 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2022 | 328 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2011 | 867 | 0.070 |
Why?
|
| Prednisone | 2 | 2004 | 104 | 0.070 |
Why?
|
| Pediatrics | 3 | 2020 | 341 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2009 | 453 | 0.070 |
Why?
|
| Ketamine | 1 | 2008 | 57 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 572 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 951 | 0.070 |
Why?
|
| Stem Cell Factor | 6 | 1995 | 39 | 0.070 |
Why?
|
| Echocardiography | 1 | 2010 | 515 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2020 | 73 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2016 | 77 | 0.070 |
Why?
|
| Respiration Disorders | 1 | 2006 | 20 | 0.070 |
Why?
|
| Allografts | 2 | 2017 | 63 | 0.070 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2018 | 24 | 0.070 |
Why?
|
| Prosthesis Failure | 2 | 2022 | 130 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 396 | 0.070 |
Why?
|
| Vitamin D | 1 | 2011 | 516 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2019 | 652 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 384 | 0.070 |
Why?
|
| Prosthesis Implantation | 2 | 2022 | 83 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1553 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 536 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 301 | 0.070 |
Why?
|
| Anemia, Megaloblastic | 1 | 1985 | 1 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2005 | 30 | 0.070 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 1985 | 2 | 0.070 |
Why?
|
| Ketone Oxidoreductases | 1 | 1985 | 2 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2005 | 32 | 0.070 |
Why?
|
| Heart Rate | 1 | 2008 | 568 | 0.070 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2005 | 24 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 57 | 0.060 |
Why?
|
| Colony-Stimulating Factors | 3 | 1990 | 19 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2006 | 328 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 2006 | 307 | 0.060 |
Why?
|
| Sepsis | 1 | 2008 | 233 | 0.060 |
Why?
|
| Hospitals | 2 | 2020 | 265 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 1995 | 489 | 0.060 |
Why?
|
| Heterozygote | 2 | 2016 | 174 | 0.060 |
Why?
|
| Deafness | 1 | 1985 | 64 | 0.060 |
Why?
|
| HLA-DR Antigens | 5 | 1995 | 41 | 0.060 |
Why?
|
| Kallikreins | 1 | 2006 | 323 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2005 | 244 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 1996 | 330 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 615 | 0.060 |
Why?
|
| Mediterranean Region | 2 | 2016 | 3 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 213 | 0.060 |
Why?
|
| Spinal Puncture | 2 | 2008 | 38 | 0.060 |
Why?
|
| Memory | 1 | 2006 | 214 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2004 | 216 | 0.060 |
Why?
|
| Lysosomes | 2 | 2020 | 136 | 0.060 |
Why?
|
| Attention | 1 | 2006 | 225 | 0.060 |
Why?
|
| Mice | 6 | 2020 | 8474 | 0.060 |
Why?
|
| Granulocytes | 4 | 1994 | 22 | 0.060 |
Why?
|
| Cells, Cultured | 9 | 1998 | 2673 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 57 | 0.060 |
Why?
|
| Transplantation, Autologous | 3 | 2014 | 145 | 0.060 |
Why?
|
| Seizures | 3 | 2011 | 279 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 517 | 0.060 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2003 | 3 | 0.060 |
Why?
|
| Vitiligo | 1 | 2003 | 12 | 0.050 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2003 | 3 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 42 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 659 | 0.050 |
Why?
|
| Life Tables | 1 | 2001 | 29 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1451 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 94 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2021 | 20 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2021 | 57 | 0.050 |
Why?
|
| Duffy Blood-Group System | 1 | 2000 | 2 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 127 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 2020 | 3 | 0.050 |
Why?
|
| Chloride Channels | 1 | 2020 | 22 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 11 | 0.050 |
Why?
|
| Fluorouracil | 3 | 1990 | 130 | 0.050 |
Why?
|
| Leukocyte Count | 4 | 2003 | 94 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2020 | 16 | 0.050 |
Why?
|
| Consanguinity | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cyclosporine | 2 | 2003 | 121 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 11 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 223 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2022 | 301 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 19 | 0.050 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2022 | 153 | 0.050 |
Why?
|
| Knowledge Management | 1 | 2020 | 2 | 0.050 |
Why?
|
| Immunosuppressive Agents | 3 | 2003 | 514 | 0.050 |
Why?
|
| Siblings | 1 | 2020 | 34 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2000 | 26 | 0.040 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 18 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2022 | 418 | 0.040 |
Why?
|
| Fatigue | 1 | 2021 | 132 | 0.040 |
Why?
|
| Fees, Medical | 1 | 1999 | 9 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 17 | 0.040 |
Why?
|
| Employment | 1 | 2021 | 154 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2020 | 132 | 0.040 |
Why?
|
| Mycoses | 1 | 2000 | 60 | 0.040 |
Why?
|
| Polymerization | 1 | 2019 | 17 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 1999 | 37 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2000 | 108 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 38 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 1985 | 694 | 0.040 |
Why?
|
| Growth Substances | 2 | 1990 | 77 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Hospital Charges | 1 | 1999 | 60 | 0.040 |
Why?
|
| Cholecystectomy | 2 | 1997 | 79 | 0.040 |
Why?
|
| Emotions | 1 | 2021 | 244 | 0.040 |
Why?
|
| Ear, Middle | 1 | 1999 | 32 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2019 | 45 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2019 | 53 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 792 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 186 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2020 | 199 | 0.040 |
Why?
|
| Cell Cycle | 3 | 1994 | 312 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 1998 | 20 | 0.040 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 41 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2018 | 7 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2018 | 71 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 38 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 148 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 107 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 2000 | 1026 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 1998 | 7 | 0.040 |
Why?
|
| Mass Screening | 1 | 2004 | 843 | 0.040 |
Why?
|
| In Vitro Techniques | 3 | 1994 | 765 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 114 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 22 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2017 | 17 | 0.040 |
Why?
|
| Clone Cells | 2 | 2014 | 67 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2017 | 41 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 27 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 23 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 63 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2005 | 86 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2019 | 311 | 0.040 |
Why?
|
| Antigens, Differentiation | 2 | 1995 | 49 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 383 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 159 | 0.040 |
Why?
|
| Decision Making | 1 | 2000 | 410 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 83 | 0.030 |
Why?
|
| Turner Syndrome | 1 | 1996 | 10 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2010 | 52 | 0.030 |
Why?
|
| Group II Phospholipases A2 | 2 | 2006 | 6 | 0.030 |
Why?
|
| Blood Platelets | 2 | 2014 | 284 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 2006 | 32 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2000 | 1664 | 0.030 |
Why?
|
| Kidney | 2 | 2016 | 945 | 0.030 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 1996 | 47 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 710 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 187 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 1995 | 18 | 0.030 |
Why?
|
| Autoantibodies | 2 | 2010 | 434 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 196 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1995 | 10 | 0.030 |
Why?
|
| Kernicterus | 1 | 1995 | 7 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 50 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 188 | 0.030 |
Why?
|
| Myoclonus | 1 | 1995 | 9 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1995 | 22 | 0.030 |
Why?
|
| Insulin | 1 | 1998 | 619 | 0.030 |
Why?
|
| Erythropoiesis | 2 | 1992 | 24 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 17 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 16 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1995 | 15 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1995 | 5 | 0.030 |
Why?
|
| Mice, SCID | 1 | 1995 | 238 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 208 | 0.030 |
Why?
|
| Mice, Nude | 1 | 1995 | 294 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 32 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2015 | 65 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 1995 | 24 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 30 | 0.030 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2014 | 6 | 0.030 |
Why?
|
| Organic Anion Transporters | 1 | 2014 | 5 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 129 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7367 | 0.030 |
Why?
|
| Cell Division | 5 | 1994 | 541 | 0.030 |
Why?
|
| Triprolidine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pseudoephedrine | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hematopoietic System | 1 | 1994 | 8 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 47 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 2014 | 22 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 22 | 0.030 |
Why?
|
| Gastritis | 1 | 2013 | 12 | 0.030 |
Why?
|
| Depression | 1 | 2021 | 943 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 733 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1994 | 66 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 138 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1994 | 59 | 0.030 |
Why?
|
| Propranolol | 1 | 2014 | 103 | 0.030 |
Why?
|
| Topotecan | 1 | 2013 | 17 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1995 | 275 | 0.030 |
Why?
|
| Morbidity | 1 | 2013 | 130 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 124 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2014 | 228 | 0.030 |
Why?
|
| Staphylococcus epidermidis | 1 | 2012 | 12 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 770 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 117 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 304 | 0.030 |
Why?
|
| Certification | 1 | 2013 | 66 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1992 | 78 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 189 | 0.030 |
Why?
|
| Neurons | 1 | 1998 | 881 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1692 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1753 | 0.030 |
Why?
|
| Colitis | 1 | 2014 | 156 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 481 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 1990 | 626 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1995 | 370 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2013 | 180 | 0.030 |
Why?
|
| Basophils | 2 | 1989 | 57 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1851 | 0.030 |
Why?
|
| Prothrombin | 1 | 2011 | 12 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 129 | 0.020 |
Why?
|
| Public Health | 1 | 2013 | 201 | 0.020 |
Why?
|
| Mast Cells | 2 | 1989 | 113 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1619 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.020 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2011 | 2 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Hemoglobinopathies | 1 | 2011 | 5 | 0.020 |
Why?
|
| Immune System Diseases | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2011 | 21 | 0.020 |
Why?
|
| Length of Stay | 1 | 1994 | 780 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2010 | 21 | 0.020 |
Why?
|
| Leg Length Inequality | 1 | 2010 | 15 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2003 | 737 | 0.020 |
Why?
|
| Paresis | 1 | 2011 | 78 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 2791 | 0.020 |
Why?
|
| Hospitals, Special | 1 | 1990 | 15 | 0.020 |
Why?
|
| Malabsorption Syndromes | 1 | 2010 | 7 | 0.020 |
Why?
|
| Moyamoya Disease | 1 | 2010 | 7 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2010 | 38 | 0.020 |
Why?
|
| Fasciculation | 1 | 2010 | 1 | 0.020 |
Why?
|
| Muscle Cramp | 1 | 2010 | 3 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2010 | 5 | 0.020 |
Why?
|
| Hyperesthesia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Electrodiagnosis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2010 | 24 | 0.020 |
Why?
|
| Tracheal Diseases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 219 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 540 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2010 | 22 | 0.020 |
Why?
|
| Zinc | 1 | 2010 | 73 | 0.020 |
Why?
|
| Bronchi | 1 | 2010 | 59 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2009 | 31 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2010 | 151 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 1989 | 33 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 97 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2010 | 49 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 2009 | 119 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2010 | 99 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2011 | 368 | 0.020 |
Why?
|
| Recurrence | 3 | 1998 | 948 | 0.020 |
Why?
|
| Medical Oncology | 1 | 1990 | 110 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1990 | 124 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 238 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 467 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 274 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 91 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 15 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 657 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 392 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2010 | 147 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2008 | 81 | 0.020 |
Why?
|
| Lung | 1 | 1993 | 849 | 0.020 |
Why?
|
| Fentanyl | 1 | 2008 | 26 | 0.020 |
Why?
|
| Lymphoma | 1 | 2008 | 116 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 63 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 711 | 0.020 |
Why?
|
| Respiration | 1 | 2008 | 91 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1995 | 1615 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2008 | 101 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 101 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 371 | 0.020 |
Why?
|
| Epinephrine | 1 | 1987 | 103 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 2 | 1998 | 35 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2009 | 382 | 0.020 |
Why?
|
| Anesthesia | 1 | 2008 | 120 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 332 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 2 | 1998 | 198 | 0.020 |
Why?
|
| Embolism, Fat | 1 | 2006 | 13 | 0.020 |
Why?
|
| Transketolase | 1 | 1985 | 1 | 0.020 |
Why?
|
| Suspensions | 2 | 2000 | 11 | 0.020 |
Why?
|
| Albumins | 1 | 2006 | 72 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 1985 | 18 | 0.020 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1985 | 9 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 1998 | 172 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2011 | 665 | 0.020 |
Why?
|
| Macaca fascicularis | 3 | 1990 | 31 | 0.020 |
Why?
|
| Meningeal Neoplasms | 1 | 2005 | 42 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1987 | 186 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2000 | 289 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2005 | 98 | 0.020 |
Why?
|
| Hydrolases | 1 | 1984 | 20 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 567 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 2 | 1994 | 7 | 0.010 |
Why?
|
| Immunomagnetic Separation | 2 | 1994 | 5 | 0.010 |
Why?
|
| Macrophages | 3 | 1994 | 647 | 0.010 |
Why?
|
| Intelligence | 1 | 2003 | 45 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 245 | 0.010 |
Why?
|
| Milk Hypersensitivity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2003 | 15 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2003 | 96 | 0.010 |
Why?
|
| Salmonella Infections | 1 | 2003 | 11 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 253 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 27 | 0.010 |
Why?
|
| Eczema | 1 | 2003 | 10 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2003 | 33 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 320 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 74 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 37 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 20 | 0.010 |
Why?
|
| Trisomy | 1 | 2003 | 47 | 0.010 |
Why?
|
| Rituximab | 1 | 2003 | 61 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2003 | 54 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 302 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 1266 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 195 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1984 | 597 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1046 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 955 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2000 | 57 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2000 | 25 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 2000 | 85 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 2000 | 54 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1999 | 49 | 0.010 |
Why?
|
| Liposomes | 1 | 2000 | 107 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2000 | 179 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 402 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1999 | 193 | 0.010 |
Why?
|
| South Carolina | 2 | 1999 | 2752 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1998 | 16 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1998 | 163 | 0.010 |
Why?
|
| Cricetinae | 1 | 1998 | 262 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1998 | 84 | 0.010 |
Why?
|
| Flavonoids | 1 | 1998 | 109 | 0.010 |
Why?
|
| Sample Size | 1 | 1998 | 79 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1998 | 78 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1998 | 249 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2000 | 448 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1995 | 13 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1998 | 1200 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 28 | 0.010 |
Why?
|
| Anemia | 1 | 1996 | 104 | 0.010 |
Why?
|
| Bilirubin | 1 | 1995 | 51 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2000 | 2077 | 0.010 |
Why?
|
| Culture Media | 1 | 1994 | 155 | 0.010 |
Why?
|
| Globins | 1 | 1994 | 13 | 0.010 |
Why?
|
| Chimera | 1 | 1994 | 33 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 110 | 0.010 |
Why?
|
| Plasma | 1 | 1994 | 58 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1994 | 122 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 128 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1994 | 282 | 0.010 |
Why?
|
| Fetus | 1 | 1994 | 157 | 0.010 |
Why?
|
| Microcirculation | 1 | 1993 | 77 | 0.010 |
Why?
|
| DNA | 1 | 1994 | 597 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 5300 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1990 | 35 | 0.010 |
Why?
|
| Cell Count | 1 | 1990 | 248 | 0.010 |
Why?
|
| Models, Biological | 1 | 1994 | 981 | 0.010 |
Why?
|
| Eosinophils | 1 | 1989 | 60 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 181 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1989 | 155 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 1047 | 0.000 |
Why?
|
| Stem Cells | 1 | 1990 | 248 | 0.000 |
Why?
|
| Antibodies | 1 | 1989 | 241 | 0.000 |
Why?
|
| Aging | 1 | 1994 | 911 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 532 | 0.000 |
Why?
|
| Extracellular Matrix | 1 | 1989 | 493 | 0.000 |
Why?
|
| alpha-L-Fucosidase | 1 | 1984 | 1 | 0.000 |
Why?
|
| alpha-Mannosidase | 1 | 1984 | 2 | 0.000 |
Why?
|
| Chromatography, Agarose | 1 | 1984 | 3 | 0.000 |
Why?
|
| Mannosidases | 1 | 1984 | 4 | 0.000 |
Why?
|
| Receptor, IGF Type 2 | 1 | 1984 | 13 | 0.000 |
Why?
|
| Extracellular Space | 1 | 1984 | 121 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1984 | 902 | 0.000 |
Why?
|